ClinicalTrials.gov
ClinicalTrials.gov Menu

Precisight® Intraocular Lens Implantation for Cataract Treatment (PEACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02970487
Recruitment Status : Recruiting
First Posted : November 22, 2016
Last Update Posted : March 13, 2018
Sponsor:
Collaborator:
Targomed
Information provided by (Responsible Party):
InfiniteVision Optics

Brief Summary:
The purpose of this study is to determine the refractive outcomes and optimize the clinical features of a new intraocular lens intended to treat the senile cataract.

Condition or disease Intervention/treatment Phase
Cataract Senile Device: Intraocular implant of the Precisight Not Applicable

Detailed Description:

InfiniteVision Optics has developed a new IOL system, the Precisight IOL. This IOL consists of a combination of two lenses: a base lens which is placed permanently into the capsular bag, and a front lens which sits on top of the base lens outside the capsular bag. The major advantage of this system is the adjustability of the primary IOL implantation which is done by front lens exchange. In case of either postoperative refractive adjustments or patient dissatisfaction with the visual performance, the front lens can be easily exchange by a less invasive surgery, avoiding a total IOL explantation. The implantation of the Precisight IOL is similar to the implantation of a traditional intraocular lens with no expected additional risk.

For all new IOLs, the IOL-constants are determined and provided by the manufacturer. They are calculated on the basis of eye models and clinical testing. In this study the biometric data of each patient's eye will be documented together with the implanted lens power and the postoperative stable refraction for calculation of the optimized IOL-constants.

In the present study, 125 subjects will be enrolled. Patients with a deviation from target refraction of more than 0.5 D spherical equivalent at the 2-3 month follow-up visit will undergo a secondary intervention for exchange of the front lens. These patients will be followed up for 1 year after front lens exchange.

Subjects will be screened during a pre-operative visit. Before the surgery visit, the subjected must have signed the Informed Consent Form.

After the surgery, patients will be followed up for one year. The visits will be scheduled at 1 day, 7-14 days, 2-3 months and 5-7 months and 1 year after surgery. Patients who underwent a surgery to exchange the front lens will be also followed up 1 day, 7-14 days, 2-3 months and 5-7 months and 1 year after the exchange surgery.

Investigator site staff will document the data in electronic Case Report Forms (eCRF). The data will be pseudonymized, i.e. only the year of birth and a code will be entered in the eCRF. Adverse events will be recorded in an eCRFs. Unexpected and serious adverse events are to be reported to the manufacturer.

Data cleaning will be done one month after last patient out and study report finished three months after last patient out. Subjects must be withdrawn from the study (i) at their own request, (ii) in case of intraoperative complication impacting the safety of the patient or (iii) in case of any postoperative complication if the continuation of the study has an impact on the safety of the patient. The study may terminate before completion if a high relative number of individual subject withdrawals due to the patient's requests and/or clinically relevant complications are observed. The IRB will be informed in due course accordingly.

The findings of this study will be published by the investigators in a scientific journal and presented at scientific meetings.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 125 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Refractive Outcome and Optimization of IOL-Constants After Implantation of the Precisight® Intraocular Lens.
Study Start Date : June 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: investigational device
Subjects implanted with the Precisight intraocular lens.
Device: Intraocular implant of the Precisight
Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.




Primary Outcome Measures :
  1. Change of the subjective refraction [ Time Frame: 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation ]
    The evolution of subjective refraction will be assessed after Precisight implantation.


Secondary Outcome Measures :
  1. Best-corrected distance visual acuity [ Time Frame: 1 day, 7 to 14 days, 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation ]
  2. Introcular lens (IOL) decentration and tilt [ Time Frame: day of surgery, 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation ]
  3. Anterior chamber depth [ Time Frame: pre-operative, 2 to 3 months, 5 to 7 months and 1 year after the investigational device implantation ]
  4. Adverse events [ Time Frame: All follow up period (1 year) ]
  5. Assessment of investigator regarding handling and achievement of target refraction [ Time Frame: Six months after investigational device implantation ]
    The investigator shall answer a questionnaire.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age-related bilateral cataract or one pseudophakic eye
  • Visual acuity potential of the study eye of at least 0.63 (decimal)
  • Expected postoperative astigmatism of ≤0.75 D in the study eye
  • IOL power within available diopters
  • Written informed patient consent regarding participation in the study and data protection

Exclusion Criteria:

  • Visually significant corneal scars
  • Ocular disorders - other than cataract - that could potentially cause future acuity losses to a level of 0.5 (decimal) or worse in the study eye
  • Relevant concomitant ophthalmic diseases (such as pseudoexfoliation, angleclosure glaucoma, traumatic cataract and other co-morbidity that could affect capsular bag stability (e.g. Marfan syndrome)
  • Participation of patient in other clinical trials (former participation is not an exclusion criterion)
  • Any cataract condition that makes the assessment of retina status difficult
  • Anyone with unstable systemic conditions or untreated systemic medical problems including but not limited to the following: Untreated diabetes, Cardiovascular untreated disease, Pulmonary untreated disease, Any untreated infection, Neuro-ophthalmologic diseases, Any allergy to the medications used during surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02970487


Contacts
Contact: Betty Chon +632 5118507 betty.chon@peregrineeye.com
Contact: Rovileen Barroquiña +632 5118507 rovileen.barroquina@peregrineeye.comv

Locations
Philippines
Peregrine Eye and Laser Institue Recruiting
Makati, Philippines, 1209
Contact: Betty Chon    +632 5118507    betty.chon@peregrineeye.com   
Sponsors and Collaborators
InfiniteVision Optics
Targomed
Investigators
Principal Investigator: Harvey S Uy, MD Peregrine Eye and Laser Institute

Responsible Party: InfiniteVision Optics
ClinicalTrials.gov Identifier: NCT02970487     History of Changes
Other Study ID Numbers: 2015-0023
First Posted: November 22, 2016    Key Record Dates
Last Update Posted: March 13, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by InfiniteVision Optics:
cataract

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases